Large-scale bioproduction system of therapeutic mRMA

Efficient eukaryotic expression system of high-quality mRNA of therapeutic and medical interest.

Engineered yeast strains have been developed to enable targeting and accumulation of large quantities of exogenous mRNA of interest in individualized intracellular vesicles that allow easy mRNA purification. These vesicles accumulate within the modified yeast, and store large quantities of the exogenous mRNA that is targeted there thanks to specifically-designed genetic modifications of the yeast. The bioproduced mRNA exhibits all features of a eukaryotic mRNA, such as a long 3’ Poly-A tail and a strong 5’ cap. The bioproduced mRNA shows higher translation rates than similar commercially available synthetic mRNAs, for high protein production. The yeast strains are easy to grow and the production capacity is versatile and can easily be up-scaled.

Competitive Advantages

Therapeutic mRNA bioproduced by our technology exhibits all properties of

mammalian RNA with significant advantages:

• a long 3’ poly-A tail that allows efficient translation and enhanced stability

• a functional 5’ cap favors mRNA splicing, stabilization, transport & translation

These two features together exert a profound positive synergistic effect on

efficiency of mRNA translation into the desired protein.

Our mRNA bioproduction technology comes with significant upsides:

• Easy purification of pure mRNA

• Possible scale-up in large incubators to produce large mRNA quantities

• Any type of RNA can be produced, up to 5000 bp

• High yield allows a cost-effective synthesis

• Rapid yeast growth for fast availability of the mRNA of interest

Development Status

• Genetically engineered producing yeast cells available

• Demonstrated higher RNA expression in dendritic cells than synthetic RNA

• High RNA yield

Business Opportunities

• High capacity and versatile bioproduction of mRNA of therapeutic interest

• Multi-stage development of mRNA of increasing quality for R&D and medical applications

• Suitable for all mRNA-based gene therapy indications, including vaccination for oncology and infectious diseases